• The importance of vitamin D in systemic and ocular wellness

    April 2013

    Stuart P. Richera, Joseph J. Pizzimenti

    Abstract

    Vitamin D is good for bones and teeth. It may also have a role in preventing andtreating diabetes, certain cancers, atherosclerosis, multiple sclerosis, hip fractures and ocularconditions such as age-related macular degeneration.

    © 2012 Spanish General Council of Optometry. Published by Elsevier España, S.L. All rightsreserved.

    Download full report here >>

  • Retinal Spectral Domain Optical Coherence Tomography in Early Atrophic Age-Related Macular Degeneration (AMD) and a New Metric for Objective Evaluation of the Efficacy of Ocular Nutrition

    November 2012

    Stuart Richer, Jane Cho, William Stiles, Marc Levin, James S. Wrobel, Michael Sinai and Carla Thomas

    Abstract:

    Purpose: A challenge in ocular preventive medicine is identification of patients with early pathological retinal damage that might benefit from nutritional intervention. The purpose of this study is to evaluate retinal thinning (RT) in early atrophic age-related macular degeneration (AMD) against visual function data from the Zeaxanthin and Visual Function (ZVF) randomized double masked placebo controlled clinical trial (FDA IND #78973).

    Read Report

  • Macular Re-pigmentation Enhances Driving Vision in Elderly Adult Males with Macular Degeneration

    April 2012

    Stuart Richer, Dong-Wouk Park, Rachel Epstein, James S. Wrobel and Carla Thomas

    Abstract

    Background:

    The risk of injury or fatality (driver, passenger or pedestrian) associated with motor vehicle accidents has been determined to increase with age, as a result of age-related declines in vision, motor and cognitive functioning. Elderly drivers with age related macular degeneration are particularly vulnerable to sensory visual impairment when driving at night, as they suffer declines in both Contrast sensitivity (CS) and Glare recovery (GR).

    Read Report

  • Molecular medicine in ophthalmic care

    December 2009

    Stuart Richer, O.D., Ph.D., William Stiles, M.D., Carla Thomas

    Background

    Lipofuscin is the most consistent and phylogenically constant morphologic marker of cellular aging. Autofluorescence of the A2E fluorophore within retinal pigment epithelial (RPE) lipofuscin affords the opportunity for noninvasive evaluation of age- and disease-related pathophysiological changes in the human retina. It is being used in National Eye Institute/Age-Related Eye Disease Study II to evaluate age-related macular degeneration (AMD) geographic atrophy expansion. Experiments show lipofuscin can be reversed in cell culture and animal models in heart, brain, spinal cord, and retinal tissues, using an array of antioxidants and iron chelators.

    Read Report

  • LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic agerelated macular degeneration to dietary supplementation with xanthophylls(abstract)

    May 2007

    Stuart Richer, O.D., Ph.D., Jenny Devenport, Ph.D., and John C. Lang, Ph.D.

    Background

    Age-related macular degeneration (ARMD) is the leading cause of vision loss in aging Western societies. The objective of the Lutein Antioxidant Supplementation Trial (LAST) was to determine whether specific dietary interventions increased macular pigment optical density (MPOD) and visual function in patients with atrophic ARMD. The current objective of LAST II is to discern those specific characteristics that increase MPOD, i.e., that might differentiate a responder from a nonresponder.

    Read Report

  • Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial)(abstract)

    April 2004

    Stuart Richer, O.D., Ph.D.; William Stiles, M.D., J.D.; Laisvyde Statkute, M.D.; Jose Pulido, M.D.; James Frankowski, M.S., Ph.D. candidatea,; David Rudy, M.D., M.P.H.c; Kevin Pei, B.S.; Michael Tsipursky, M.S.; and Jill Nyland, R.N.

    Background

    Age-related macular degeneration (ARMD) is the leading cause of vision loss in aging Western societies. The objective of the lutein antioxidant supplementation trial (LAST) is to determine whether nutritional supplementation with lutein or lutein together with antioxidants, vitamins, and minerals, improves visual function and symptoms in atrophic ARMD.

    Read Report

  • Treatment: For Failing Eyes, a Dose of Green

    April 2004

    By John O’Neill, THE NEW YORK TIMES

    Supplements containing lutein, a pigment found in dark green vegetables, improved the vision of men with age-related macular degeneration, a study has found. Age-related macular degeneration is the most common cause of vision loss in developed countries. Low levels of lutein consumption had previously been shown to be associated with higher risks for developing the disorder.

    Read Report

  • Plant Pigment May Reverse Vision Loss

    April 2004

    By Thomas H. Maugh II, LOS ANGELES TIMES

    Lutein, a yellow pigment found in dark green leafy vegetables like spinach, kale and collard greens, can reverse some of the symptoms of age-related macular degeneration, the leading cause of visual disability in the United States, according to a new study.

    Read Report

Next Entries »